Kamolyut Lapumnuaypol

Kamolyut Lapumnuaypol practices at Sanford Medical Center - Unit in Sioux Falls, South Dakota.

Kamolyut Lapumnuaypol's NPI, 1912357823, was assigned on June 21, 2016. Kamolyut Lapumnuaypol holds South Dakota license 14479.

Kamolyut Lapumnuaypol's primary practice is Sanford Medical Center - Unit, at 1305 W 18th Street, Sioux Falls, SD 57117 in Minnehaha County. The practice phone is (605) 328-6758.

Kamolyut Lapumnuaypol's primary practice is Sanford Medical Center - Unit in Sioux Falls, South Dakota. Kamolyut Lapumnuaypol is also affiliated with Sanford USD Medical Center. The medical group on file is Edith Sanford Breast Center Sioux Falls. Dmand AI also links Kamolyut Lapumnuaypol to 1 more hospital, 1 imaging center and 1 medical group, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Kamolyut Lapumnuaypol practices, 4 sites in all. Vendor and product names are available with a free account.

Gastroenterology is Kamolyut Lapumnuaypol's primary specialty in the NPI Registry, under taxonomy code 207RG0100X. Kamolyut Lapumnuaypol is licensed in South Dakota.

CMS data shows 188 Medicare services from Kamolyut Lapumnuaypol across 4 procedure codes in 2024, for 164 Medicare patients. Medicare paid $19,735 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 164 Medicare patients who saw Kamolyut Lapumnuaypol in 2024. The largest group is 75 to 84, with 63 patients. 75% of them have high blood pressure, and 75% have high cholesterol. 16% are also on Medicaid. Their average risk score is 2.01, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Kamolyut Lapumnuaypol's median patient age at 73, with 56% women.

In 2024, Kamolyut Lapumnuaypol wrote 84 Medicare Part D claims for 40 patients. 88% of them were for generic drugs. CMS names the drug for 66 of them, across 3 drugs with 11 or more claims each, at $739 in total drug cost. In 2023, CMS named 12 claims across 1 drug.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 85 out of 100 for Kamolyut Lapumnuaypol for performance year 2024, reported as part of a group. Kamolyut Lapumnuaypol accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS counts 57 procedures of upper gastrointestinal (gi) endoscopy for acid reflux by Kamolyut Lapumnuaypol, more than 66% of the clinicians it reports for that procedure.

CMS Open Payments shows 3 general payments to Kamolyut Lapumnuaypol from 3 drug and device companies from 2019 to 2025. Food and beverage make up the largest share, 100% of the total. Celgene Corporation paid the most, $22.